RT Journal Article SR Electronic T1 Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.02.21250836 DO 10.1101/2021.02.02.21250836 A1 Molly A. Vickers A1 Alan Sariol A1 Judith Leon A1 Alexandra Ehlers A1 Aaron V. Locher A1 Kerry A. Dubay A1 Laura Collins A1 Dena Voss A1 Abby E. Odle A1 Myrl Holida A1 Anna E. Merrill A1 Stanley Perlman A1 C. Michael Knudson YR 2021 UL http://medrxiv.org/content/early/2021/02/05/2021.02.02.21250836.abstract AB Background With the recent approval of COVID-19 vaccines, recovered COVID-19 subjects who are vaccinated may be ideal candidates to donate COVID-19 convalescent plasma (CCP).Case Series Three recovered COVID-19 patients were screened to donate CCP. All had molecularly confirmed COVID-19, and all were antibody positive by chemiluminescence immunoassay (DiaSorin) prior to vaccination. All were tested again for antibodies 11 to 21 days after they received the first dose of the vaccine (Pfizer). All showed dramatic increases (∼50 fold) in spike-specific antibody levels and had at least a 20-fold increase in the IC50 neutralizing antibody titer based on plaque reduction neutralization testing (PRNT). The spike-specific antibody levels following vaccination were significantly higher than those seen in any non-vaccinated COVID-19 subjects tested to date at our facility.Conclusion Spike-specific and neutralizing antibodies demonstrated dramatic increases following a single vaccination post COVID-19 infection which significantly exceeded values seen with COVID-19 infection alone. Recovered COVID-19 subjects who are vaccinated may make ideal candidates for CCP donation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding at this time.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Iowa IRB approved this study (IRB#202003554) and all subjects provided their consent to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified data described in this manuscript is available if needed.